Details of Disease

General Information of Disease (ID: DIS87TGM)

Disease Name Acute lymphoblastic leukaemia
Disease Class 2A85: Mature B-cell lymphoma
Disease Hierarchy
DIS01GPL: Grass pollen hypersensitivity
DIS87TGM: Acute lymphoblastic leukaemia
ICD Code
ICD-11
ICD-11: 2A85
ICD-10
ICD-10: C91.0
Expand ICD-11
'2A7Z
Expand ICD-10
'C91.0
Disease Identifiers
MONDO ID
MONDO_0004967
UMLS CUI
C0023449
MedGen ID
7317
HPO ID
HP:0006721
Orphanet ID
513
SNOMED CT ID
91857003

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)
This Disease is Treated as An Indication in 16 Approved Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Amsacrine DMZKYIV Approved Small molecular drug [1]
Arsenic trioxide DM61TA4 Approved Small molecular drug [2]
Asparaginase Erwinia chrysanthemi DMMWWH5 Approved NA [3]
Axicabtagene ciloleucel DMYHN59 Approved CAR T Cell Therapy [4]
Blinatumomab DMGECIJ Approved Monoclonal antibody [5]
Calaspargase pegol DMQZBXI Approved Antibody [6]
Clofarabine DMCVJ86 Approved Small molecular drug [7]
Cytarabine DMZD5QR Approved Small molecular drug [8]
Imatinib DM7RJXL Approved Small molecular drug [3]
Inotuzumab ozogamicin DMAC130 Approved Antibody [9]
Mercaptopurine DMTM2IK Approved Small molecular drug [10]
Ponatinib DMYGJQO Approved Small molecular drug [11]
Teniposide DMLW57T Approved Small molecular drug [12]
Tisagenlecleucel DMM9BJD Approved CAR T Cell Therapy [13]
Vincristine DMINOX3 Approved Small molecular drug [14]
Vindesine DMVR628 Approved Small molecular drug [15]
------------------------------------------------------------------------------------
⏷ Show the Full List of 16 Drug(s)
This Disease is Treated as An Indication in 89 Clinical Trial Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
AEZS-108 DMAYO46 Phase 3 Small molecular drug [16]
ATIR101 DMRV7T7 Phase 3 Cell therapy [17]
DFP-10917 DM1WNGJ Phase 3 Small molecular drug [18]
Epratuzumab DMI1ZXV Phase 3 Antibody [19]
GRASPA DM4Y7WV Phase 3 Protein [20]
ICLUSIG DM1SQSE Phase 3 Small molecule [21]
NiCord DMTSURO Phase 3 NA [22]
CART-19 DMST3FM Phase 2/3 CAR T Cell Therapy [23]
CD19 CAR T cells DM32148 Phase 2/3 CAR T Cell Therapy [24]
ADCT-301 DMY78E0 Phase 2 NA [19]
BL-22 DM8R71T Phase 2 Antibody [25]
BP-100-1-01 DMKDGI8 Phase 2 NA [26]
CART 19 DMTBFXW Phase 2 CAR T Cell Therapy [27]
CART-19 DMHQKN6 Phase 2 CAR T Cell Therapy [28]
CD19-targeted allogeneic T-cell therapy DMYWRBV Phase 2 NA [29]
CTL019 DMMPC6W Phase 2 CAR T Cell Therapy [30]
DS-3201b DMI69E5 Phase 2 Small molecular drug [31]
JCAR015 DM89ASO Phase 2 CAR T Cell Therapy [22]
KYMRIAH DM15RZO Phase 2 CAR T Cell Therapy [32]
OBI-3424 DM5D6Y7 Phase 2 Small molecular drug [33]
SGN-CD19A DMS90CU Phase 2 NA [34]
Anti-CD19 CAR-T DM04HNB Phase 1/2 CAR T Cell Therapy [35]
Anti-CD19 CAR-T cells DM92CUG Phase 1/2 CAR T Cell Therapy [36]
Anti-CD19-CAR vector-transduced T cells DMQXU4C Phase 1/2 CAR T Cell Therapy [37]
Anti-CD19/22-CAR vector-transduced T cells DMMUSHR Phase 1/2 CAR T Cell Therapy [38]
Anti-CD20-CAR vector-transduced autologous T cells DMCDUJY Phase 1/2 CAR T Cell Therapy [39]
AUTO1 DMG9OAV Phase 1/2 CAR T Cell Therapy [40]
AUTO3 DMC5NSO Phase 1/2 CAR T Cell Therapy [41]
Autologous Anti-CD19CAR-4-1BB-CD3zeta-EGFRt-expressing T Lymphocytes DM2YTGQ Phase 1/2 CAR T Cell Therapy [42]
BPX-501 DMIMA4V Phase 1/2 NA [19]
CART-19 cells DMWYT4K Phase 1/2 CAR T Cell Therapy [43]
CD137 CAR-T Cell DMHMC19 Phase 1/2 CAR T Cell Therapy [44]
CD19 CAR T cells DMMHLJQ Phase 1/2 CAR T Cell Therapy [45]
CD19 CAR T Cells DMUARWH Phase 1/2 CAR T Cell Therapy [46]
CD19 CAR-T Cells DMECGKO Phase 1/2 CAR T Cell Therapy [47]
CD19 CAR-T lymphocytes DM8KESD Phase 1/2 CAR T Cell Therapy [48]
CD19 CART DM69A1W Phase 1/2 CAR T Cell Therapy [49]
CD19-CAR T cell DMQE7TW Phase 1/2 CAR T Cell Therapy [50]
CD19.CAR T Cells DM79GPF Phase 1/2 CAR T Cell Therapy [51]
CD38 CAR-T Cell DM0USBX Phase 1/2 CAR T Cell Therapy [52]
CLIC-1901 DML8US9 Phase 1/2 CAR T Cell Therapy [53]
DCC-2036 DMJKFNU Phase 1/2 Small molecular drug [54]
EPZ-5676 DMN2FS3 Phase 1/2 Small molecular drug [22]
Humanized CD19 CAR-T cells DMOVF6E Phase 1/2 CAR T Cell Therapy [55]
IC9/CAR.19/IL15-transduced CB-NK cells DMD3Y27 Phase 1/2 NA [19]
OVI-123 DMH7P48 Phase 1/2 NA [56]
PBCAR0191 DMJC2RU Phase 1/2 CAR T Cell Therapy [57]
SJCAR19 DMSOX57 Phase 1/2 CAR T Cell Therapy [58]
TBI-1501 DM5NICF Phase 1/2 CAR T Cell Therapy [59]
TC-110 DMR65X7 Phase 1/2 TCR-T cell therapy [60]
ADCT-402 DMCBIKO Phase 1 NA [4]
Anti-CD19 EBV CTL therapy DMUVYC5 Phase 1 CAR T Cell Therapy [61]
Anti-CD19-CAR DMWKYSM Phase 1 CAR T Cell Therapy [62]
CAR-T Cells targeting CD19 DM3AHNX Phase 1 CAR T Cell Therapy [63]
CART-10 cells DMQ4UJ6 Phase 1 CAR T Cell Therapy [64]
CART-19 DM8R2ZX Phase 1 CAR T Cell Therapy [65]
CART-19 cells DMHWVY1 Phase 1 CAR T Cell Therapy [64]
CART-19 cells DMKW27X Phase 1 CAR T Cell Therapy [66]
CART-20 cells DMR0Z65 Phase 1 CAR T Cell Therapy [64]
CART-22 cells DMLGJKE Phase 1 CAR T Cell Therapy [64]
CART22 cells DM6X82R Phase 1 CAR T Cell Therapy [67]
CART22 cells expressing anti-CD22 scFv TCRz:41BB DMY3NWK Phase 1 CAR T Cell Therapy [68]
CART22-65s cells DM4XT15 Phase 1 CAR T Cell Therapy [69]
CART22-65s cells and huCART19 Cells DMOJ1AH Phase 1 CAR T Cell Therapy [69]
CD19 CAR T DM4PWNU Phase 1 CAR T Cell Therapy [70]
CD19 CAR T cells DMB8RI6 Phase 1 CAR T Cell Therapy [71]
CD19 CAR T-cells DMJCT6Q Phase 1 CAR T Cell Therapy [72]
CD19 CAR-T cells DM6GNDP Phase 1 CAR T Cell Therapy [73]
CD19 CAR-T cells DMNDACU Phase 1 CAR T Cell Therapy [74]
CD19-CAR and CD28-CAR T Cells DMUR1MN Phase 1 CAR T Cell Therapy [75]
CD19-CAR-T Cells DMJIW5Z Phase 1 CAR T Cell Therapy [76]
CD19-CAR-T2 Cells DML07UZ Phase 1 CAR T Cell Therapy [77]
CD19/CD22 CAR T cells DMVONF0 Phase 1 CAR T Cell Therapy [78]
CD19/CD22 Chimeric Antigen Receptor T Cells DMPADR1 Phase 1 CAR T Cell Therapy [79]
CD19CAT-41BBZ CAR T-cells DM3LRAF Phase 1 CAR T Cell Therapy [80]
CD28 and CD137 CAR-T Cells DMFGQXB Phase 1 CAR T Cell Therapy [81]
DS-3201 DMRLPFG Phase 1 NA [19]
IC9-CAR19 cells DMP1ZF8 Phase 1 CAR T Cell Therapy [82]
JCAR018 DMR3SO5 Phase 1 NA [4]
KTE-C19 DMO1U56 Phase 1 NA [19]
MGD006 DMQB4VN Phase 1 Monoclonal antibody [83]
MLN-576 DMCVO2Y Phase 1 NA [84]
OTSSP167 DMF5KNO Phase 1 Small molecular drug [19]
PZ01 CAR-T cells DMRGWDB Phase 1 CAR T Cell Therapy [85]
ROR1 CAR-specific Autologous T-Lymphocytes DM5EUIY Phase 1 CAR T Cell Therapy [86]
Anti-CD19/20-CAR vector-transduced T cells DM3M9OY Clinical trial CAR T Cell Therapy [87]
CD19-CAR T Cells DM2V6R7 Clinical trial CAR T Cell Therapy [88]
CD19-UCART DM8VTF2 Clinical trial CAR T Cell Therapy [89]
GR148672X DM7W6YN Clinical trial Small molecular drug [90]
------------------------------------------------------------------------------------
⏷ Show the Full List of 89 Drug(s)
This Disease is Treated as An Indication in 2 Discontinued Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
SCH 727965 DMCJLD1 Discontinued in Phase 3 Small molecular drug [91]
Banoxantrone DMK5I07 Discontinued in Phase 1 Small molecular drug [92]
------------------------------------------------------------------------------------
This Disease is Treated as An Indication in 4 Investigative Drug(s)
Drug Name Drug ID Highest Status Drug Type REF
Anti-CD22/CD19 mab-toxin conjugate DM8QIB2 Investigative Monoclonal antibody [93]
Recombinant L-asparaginase DM6F71N Investigative NA [94]
TN-14003 DME0I7O Investigative NA [95]
UNC569 DMJL6ZM Investigative Small molecular drug [96]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

References

1 Identification of FDA-approved drugs and bioactives that protect hair cells in the zebrafish (Danio rerio) lateral line and mouse (Mus musculus) ut... J Assoc Res Otolaryngol. 2009 Jun;10(2):191-203.
2 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 078729.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 ClinicalTrials.gov (NCT02013167) Blinatumomab Versus Standard of Care Chemotherapy in Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia (ALL)
6 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800034060)
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6802).
8 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4827).
9 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8266).
10 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7226).
11 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5890).
12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6843).
13 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
14 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6785).
15 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
16 ClinicalTrials.gov (NCT01767155) Study Comparing AEZS-108/ZoptEC (Zoptarelin Doxorubicin in Endometrial Cancer) to Doxorubicin as a Second Line Therapy of Endometrial Cancer. U.S. National Institutesof Health.
17 ClinicalTrials.gov (NCT02999854) Safety and Efficacy of ATIR101 as Adjunctive Treatment to Blood Stem Cell Transplantation From a Haploidentical Family Donor Compared to Post-transplant Cyclophosphamide in Patients With Blood Cancer (HATCY). U.S. National Institutes of Health.
18 ClinicalTrials.gov (NCT01702155) Phase I/II Study of DFP-10917 in Patients With Acute Leukemia. U.S. National Institutes of Health.
19 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
20 ClinicalTrials.gov (NCT01518517) GRASPA (Erythrocytes Encapsulating L-asparaginase) in Patients With Relapse of Acute Lymphoblastic Leukemia (GRASPIVOTALL). U.S. National Institutes of Health.
21 ClinicalTrials.gov (NCT03589326) A Phase 3, Randomized, Open-label, Multicenter Study Comparing Ponatinib Versus Imatinib, Administered in Combination With Reduced-Intensity Chemotherapy, in Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ ALL). U.S.National Institutes of Health.
22 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
23 ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL
24 ClinicalTrials.gov (NCT03391739) CART-19 Cells For R/R B-ALL
25 ClinicalTrials.gov (NCT00924040) Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia. U.S. National Institutes of Health.
26 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800032443)
27 ClinicalTrials.gov (NCT02935543) CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL
28 ClinicalTrials.gov (NCT01029366) CART19 to Treat B-Cell Leukemia or Lymphoma That Are Resistant or Refractory to Chemotherapy
29 CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Blood. 2015 Jun 25;125(26):4017-23.
30 ClinicalTrials.gov (NCT03601442) CTL019 Out of Specification MAP for ALL or DLBCL Patients
31 ClinicalTrials.gov (NCT03110354) DS-3201b for Acute Myelogenous Leukemia (AML) or Acute Lymphocytic Leukemia (ALL). U.S. National Institutes of Health.
32 ClinicalTrials.gov (NCT03642626) MT2017-45 :CAR-T Cell Therapy for Heme Malignancies
33 ClinicalTrials.gov (NCT04315324) Study to Test AKR1C3-Activated Prodrug OBI-3424 (OBI-3424) in Patients With Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL). U.S. National Institutes of Health.
34 ClinicalTrials.gov (NCT01786135) A Safety Study of SGN-CD19A for B-Cell Lymphoma. U.S. National Institutes of Health.
35 ClinicalTrials.gov (NCT03110640) Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma
36 ClinicalTrials.gov (NCT03366324) Anti-CD19 CAR-T Therapy Combine With HSCT to Treat MRD+ B-cell Malignancies
37 ClinicalTrials.gov (NCT01864889) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by CART19
38 ClinicalTrials.gov (NCT03185494) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD22
39 ClinicalTrials.gov (NCT01735604) Genetically Engineered Lymphocyte Therapy in Treating Patients With Lymphoma That is Resistant or Refractory to Chemotherapy
40 ClinicalTrials.gov (NCT04404660) A Study of CD19 Targeted CAR T Cell Therapy in Adult Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukaemia (ALL). U.S. National Institutes of Health.
41 ClinicalTrials.gov (NCT03289455) CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL
42 ClinicalTrials.gov (NCT01865617) Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non-Hodgkin Lymphoma, or Acute Lymphoblastic Leukemia
43 ClinicalTrials.gov (NCT03544021) CART-19 FOR Relapsed/Refractory Acute Lymphoblastic Leukemia ALL
44 ClinicalTrials.gov (NCT02965092) CD19 Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With B-cell Malignancies
45 ClinicalTrials.gov (NCT02772198) T-cells Expressing Anti-CD19 CAR in Pediatric and Young Adults With B-cell Malignancies
46 ClinicalTrials.gov (NCT01475058) CD19 CAR T Cells for B Cell Malignancies After Allogeneic Transplant
47 ClinicalTrials.gov (NCT03263208) CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
48 ClinicalTrials.gov (NCT03467256) CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
49 ClinicalTrials.gov (NCT03232619) CD19-CART Treatment for ALL
50 ClinicalTrials.gov (NCT03373071) Anti-CD19 CAR T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and NHL
51 ClinicalTrials.gov (NCT03676504) Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR
52 ClinicalTrials.gov (NCT03754764) A Feasibility and Safety Study of CD38 CAR-T Cell Immunotherapy for Relapsed B-cell Acute Lymphoblastic Leukemia After CD19 CAR-T Adoptive Cellular Immunotherapy
53 ClinicalTrials.gov (NCT03765177) CLIC-1901 for the Treatment of Patients With Relapsed/Refractory CD19 Positive Hematologic Malignancies
54 ClinicalTrials.gov (NCT00827138) Study Safety and Preliminary Efficacy of DCC-2036 in Patients With Leukemias (Ph+ CML With T315I Mutation). U.S. National Institutes of Health.
55 ClinicalTrials.gov (NCT03275493) Humanized CD19 CAR-T Cells With CRS Suppression Technology for r/r CD19+ Acute Lymphoblastic Leukemia
56 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028636)
57 ClinicalTrials.gov (NCT03666000) Dose-escalation Study of Safety of PBCAR0191 in Patients With r/r NHL and r/r B-cell ALL
58 ClinicalTrials.gov (NCT03573700) Evaluation of CD19-Specific CAR Engineered Autologous T-Cells for Treatment of Relapsed/Refractory CD19+ Acute Lymphoblastic Leukemia
59 ClinicalTrials.gov (NCT03155191) Study of TBI-1501 for Relapsed or Refractory Acute Lymphoblastic Leukemia
60 ClinicalTrials.gov (NCT04323657) TC-110 T Cells in Adults With Relapsed or Refractory Non-Hodgkin Lymphoma or Acute Lymphoblastic Leukemia. U.S. National Institutes of Health.
61 ClinicalTrials.gov (NCT00840853) Multi-virus CTLs Expressing CD19 Chimeric Receptors, CD19 Positive Malignancies Post SCT, MULTIPRAT (MULTIPRAT). U.S. National Institutes of Health.
62 ClinicalTrials.gov (NCT01593696) Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma
63 ClinicalTrials.gov (NCT03186118) Pilot Study of T-APCs Following CAR T Cell Immunotherapy for CD19+ Leukemia
64 ClinicalTrials.gov (NCT03291444) CAR-T Cells Combined With Peptide Specific Dendritic Cell in Relapsed/Refractory Leukemia/MDS
65 ClinicalTrials.gov (NCT02810223) Efficacy of CART-19 Cell Therapy in B Cell Acute Lymphoblastic Leukemia
66 ClinicalTrials.gov (NCT02924753) The Safety and Efficacy of CART-19 Cells in B-cell Acute Lymphoblastic Leukemia (B-ALL).
67 ClinicalTrials.gov (NCT02588456) Pilot Study of Autologous Anti-CD22 Chimeric Antigen Receptor Redirected T Cells In Patients With Chemotherapy Resistant Or Refractory Acute Lymphoblastic Leukemia
68 ClinicalTrials.gov (NCT02650414) CD22 Redirected Autologous T Cells for ALL
69 ClinicalTrials.gov (NCT03620058) CART22 Alone or in Combination With huCART19 for ALL
70 ClinicalTrials.gov (NCT03559439) CD19-targeting CAR T Cells in Relapsed or Refractory CD19 Positive B-cell Malignancies
71 ClinicalTrials.gov (NCT02975687) CD19 CAR T Cells in Patients With Resistant or Refractory CD19+ Acute Lymphoblastic Leukemia
72 ClinicalTrials.gov (NCT02443831) CARPALL: Immunotherapy With CD19 CAR T-cells for CD19+ Haematological Malignancies
73 ClinicalTrials.gov (NCT03671460) CD19 CAR-T Cells for Patients With Relapse and Refractory CD19+ B-ALL.
74 ClinicalTrials.gov (NCT03064269) CAR-T Therapy for Central Nervous System B-cell Acute Lymphocytic Leukemia
75 ClinicalTrials.gov (NCT02146924) Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia
76 ClinicalTrials.gov (NCT03574168) CD19-CAR-T Cells in Patients With R/R B-ALL
77 ClinicalTrials.gov (NCT02822326) Phase I Study of CD19-CAR-T2 Cells for Patients With Chemotherapy Resistant or Refractory CD19+ Acute Leukemia
78 ClinicalTrials.gov (NCT03241940) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Children or Young Adults With Recurrent or Refractory CD19 Positive B Acute Lymphoblastic Leukemia
79 ClinicalTrials.gov (NCT03233854) CD19/CD22 Chimeric Antigen Receptor T Cells and Chemotherapy in Treating Patients With Recurrent or Refractory CD19 Positive Diffuse Large B-Cell Lymphoma or B Acute Lymphoblastic Leukemia
80 ClinicalTrials.gov (NCT02935257) Immunotherapy for High Risk/Relapsed CD19+ Acute Lymphoblastic Leukaemia Using CAR T-cells to Target CD19
81 ClinicalTrials.gov (NCT02186860) Chimeric Antigen Receptor (CAR)-Modified T Cell Therapy in Treating Patients With Acute Lymphoblastic Leukemia
82 ClinicalTrials.gov (NCT03016377) Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia
83 A Phase I trial of MGD006 in patients with relapsed acute myeloid leukemia (AML). J Immunother Cancer. 2014; 2(Suppl 3): P87.
84 In vitro and in vivo characterization of XR11576, a novel, orally active, dual inhibitor of topoisomerase I and II. Anticancer Drugs. 2002 Jan;13(1):15-28.
85 ClinicalTrials.gov (NCT03281551) Efficacy and Safety of PZ01 Treatment in Patients With r/r CD19+ B-cell Acute Lymphoblastic Leukemia/B Cell Lymphoma
86 ClinicalTrials.gov (NCT02706392) Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
87 ClinicalTrials.gov (NCT03097770) Treatment of Relapsed and/or Chemotherapy Refractory B-cell Malignancy by Tandem CAR T Cells Targeting CD19 and CD20
88 ClinicalTrials.gov (NCT03423706) Clinical Studies of New Model Haploidentical Hematopoietic Stem Cell Transplantation
89 ClinicalTrials.gov (NCT03229876) Safety and Efficacy Evaluation of CD19-UCART
90 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6701).
91 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7379).
92 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004590)
93 Immunotoxins against CD19 and CD22 are effective in killing precursor-B acute lymphoblastic leukemia cells in vitro. Leukemia. 2000 May;14(5):853-8.
94 The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
95 Discovery of small molecule CXCR4 antagonists. J Med Chem. 2007 Nov 15;50(23):5655-64.
96 UNC569, a novel small-molecule mer inhibitor with efficacy against acute lymphoblastic leukemia in vitro and in vivo. Mol Cancer Ther. 2013 Nov;12(11):2367-77.
97 ClinicalTrials.gov (NCT02968472) A Phase I Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Leukemia